Epion Therapeutics is developing a minimally -invasive treatment for ectatic corneal disease that can bring early intervention to millions of patients globally.  Our EpiSmart approach is a transformative cross-linking system designed to treat keratoconus without  disrupting  the epithelium, allowing for a  rapid return to normal activities. Phase 3 clinical trials are underway with results expected in Q1 2026.